AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Beauty Health to report Q2 2025 results on Aug 7, 2025.
ByAinvest
Thursday, Jul 24, 2025 10:04 am ET1min read
• Beauty Health Company reports Q2 2025 results on August 7, 2025. • Hydrafacial is its flagship brand. • Conference call at 4:30 p.m. ET on August 7, 2025. • Webcast and supporting materials available on investor relations website.
The Beauty Health Company (NASDAQ: SKIN), a medtech meets beauty company known for its flagship brand Hydrafacial™, has scheduled its second quarter 2025 financial results for August 7, 2025. The company will release its earnings after the market close, followed by an investor conference call at 4:30 p.m. Eastern Time. Investors and interested parties can access the live webcast and supporting materials through the company's investor relations website [1].The Beauty Health Company, which delivers millions of skin health experiences annually, is committed to personalizing skin health for all ages, genders, skin tones, and skin types. Its portfolio includes Hydrafacial™ in hydradermabrasion, SkinStylus™ in microneedling, and Keravive™ in scalp health. The company has a strong global presence with over 35,000 active devices globally [2].
In the first quarter of 2025, the company reported net sales of $69.6 million, down 14.5% from the same period last year. Despite the decrease in sales, the company showed improved profitability metrics with a gross margin of 69.8% and an Adjusted EBITDA of $7.3 million [3]. The active install base grew to 35,014 units, supporting resilient consumables revenue.
The Beauty Health Company has also been actively expanding its product offerings. In June, it launched HydraFillic with Pep9™ Booster, a new peptide-powered skin treatment for its Hydrafacial brand [4]. This product features a proprietary complex of nine peptides clinically proven to improve fine lines, wrinkles, and skin firmness.
The company has announced a convertible debt refinancing, exchanging $413.2 million of its existing 1.25% convertible senior notes due 2026 for $250.0 million of new 7.95% convertible senior secured notes due 2028, plus approximately $143.4 million in cash [5]. This transaction aims to extend debt maturity and strengthen the company's financial position for growth initiatives.
The Beauty Health Company maintains transparency through various communication channels, including SEC filings, press releases, public conference calls, and its investor relations website [3]. This ensures compliance with Regulation FD disclosure obligations.
Investors are encouraged to stay tuned for the second quarter 2025 financial results and the subsequent investor conference call for insights into the company's performance and future growth prospects.
References:
[1] https://www.marketscreener.com/news/beautyhealth-to-report-second-quarter-2025-financial-results-on-august-7-2025-ce7c5cd3d08ff025
[2] https://www.stocktitan.net/news/SKIN/
[3] https://www.stocktitan.net/news/SKIN/05/08/2025-0405-PM/
[4] https://www.stocktitan.net/news/SKIN/06/04/2025-0800-AM/
[5] https://www.stocktitan.net/news/SKIN/05/21/2025-0800-AM/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet